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1. Introduction 
Many attempts have been made to improve the 
specificity of action of antitumour drugs so that their 
cytotoxicity should be concentrated in malignant 
cells. As a result of encouraging clinical trials [ 1,2] 
interest increased recently in the use of larger molec- 
ular weight materials as carriers of cytotoxic drugs. It 
was postulated that the resulting conjugates might be 
taken up selectively by tumour endocytosis [ 11. 
Daunorubicin was administered as its intercalated 
complex with DNA [ 11, antimetabolites have been 
covalently bound to globulin [3], while alkylating 
agents have been found to fibrinogen, albumin, 
globulin and their polypeptidyl derivatives [4,5]. One 
interesting finding was that the nitrogen mustards 
merely absorbed to protein, i.e., as complexes could 
also be more selective than the mustard alone [4,6]. 
A detailed investigation seemed necessary to elucidate 
the factors influencing the establishment of favourable 
transport forms. The comparison of the biological 
properties of a series of complexes [6] suggested, that 
the specificity of protein binding hinges mainly on 
the carrier part of the alkylating agents. 
In the search for new approaches to study the 
mechanism of carrier function we have started 
experiments to analyse the interaction of peptide- 
type carriers with biopolymers, e.g. with DNA [7] 
and with proteins. The subject of the present paper 
is the investigation of the binding of L-phenylalanine 
and its methyl ester (the carrier part of Melphalan) to 
human serum albumin (HSA). Furthermore a series 
of dipeptides and dipeptide esters containing aromatic 
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amino acids were prepared and their binding to HSA 
measured. 
HSA seemed a suitable choice since it was one of 
the carriers previously applied [4-61 and at the 
same time it is a widely used standard substance in 
protein investigations because many drugs are bound 
to plasma albumin [8]. 
The measurements have been made by the classical 
equilibrium dialysis method [8,9]. 
2. Experimental 
The ultraviolet absorption spectra were obtained 
in a Beckman DU (G2400) spectrophotometer, or 
with Unicam SP 700 and Specord UV VIS recording 
spectrophotometers. All solutions were filtered on 
Sartorius filters SM 11306 (0.45 pm). 
Details of the experimental procedure were des- 
cribed elsewhere [lo]. Negligible amounts of the 
small molecules were found to be bound to the 
membrane. The protein concentration used in these 
experiments was 1.43 X 10m4 M (1% solution). All 
experiments were carried out at 4°C. 
HSA was obtained from ‘Human’ Serum and 
Vaccine Institute, Budapest and was further purified 
by dialysis and freeze-drying. The molecular weight 
of HSA was taken (69 000) [ 1 l] and the e:TO as 5.3 
[ 121. The albumin was homogeneous by electro- 
phoresis on acetylated cellulose at pH 8.6. 
Amino acids were purchased from Reanal 
(Budapest). Amino acid and peptide derivatives were 
prepared in our laboratory, partly according to 
North-Holland Publishing Company - Amsterdam 
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Table 1 
Compoundalb Molar Wave- Cont. range Time req. pHd 
ext. coeff. length investigated for equil. 
(nm) (M) (hr) 
Phe (Reanal) 195.1 257.5 339 x lo-3 9 9 
193 257.5 3-9x lo-J 9 7.35 
DL@-Phe-Ser (Reanal) 201.2 258 2-5 x 10-3 24 7.35 
PheOMe.HCl [ 131 187.5 257.5 2-7 X 1O-3 24 6 
Glu-Phe [ 141 217.8 257.5 2-8 x lO-3 16 7.35 
Glu(OMe)-PheOMe.H@ 180.5 257.5 2-7 X 1O-3 24 6 
Glu(PheOMe)-OH.HCIC 183.1 257.5 2-7 X lo-’ 24 6 
Pro-PheOMe.HCl [ 151 205.5 257.5 2-7 x lo-’ 24 6 
Qu(OMe)-TyrOMe.HCIC 1102.5 274 2x lO-4-l X lo-’ 24 6 
Glu(OH)-TyrOMe.H@ 1201 275 4.5 x 1O-4-2 X lo-’ 24 6 
Se-TyrOMe.HCl [ 16) 1295.6 275 3 x lO-4-2x lo-’ 24 6 
Lys-TyrOMe. 2 HCl [ 71 1265.2 275 4 x lo-“-2 x lo-’ 24 6 
Se-TrpOMe.HCl [ 161 5161.6 279 6 x 1O-5-l x 10.’ 24 6 
Lys-TrpOMe.ZHQ [ 71 4931.4 279 7 x 10-‘-8x 1O-4 24 6 
a Amino acids are of L configuration unless otherwise stated. 
b Compounds were checked for purity by microanalyses and TLC. 
c Prepared by the mixed anhydride method: the dipeptide esters isolated as hydrochlorides are 
d 
amorphous, hygroscopic solids. 
The following buffers were used: pH 9, 0.05 M Tris-HCl; pH 7.35 and PH 6, 0.1 M phosphate. 
literature methods, partly by using the mixed anhydride 
method for coupling N-benzyloxycarbonyl-protected 
amino acids With the appropriate amino acid esters, 
followed by the removal of the protecting groups 
by catalytic hydrogenation. 
In table 1 are listed the compounds studied, with 
references to the method of preparation, to values 
used for the spectrophotometric determination of the 
concentration of the compounds in the ultraviolet 
region and to the experimental conditions used in the 
equilibrium dialysis experiments. 
The UV absorption spectra of the compounds did 
not change significantly in the presence of varying 
amounts of HSA. The presence of Cl- ions in the 
range 0.005 M-0.0001 M did not influence the 
binding of dipeptide esters. This is in agreement with 
the results of McMenamy [ 171 who reported that 
only with negatively charged indole derivatives, like 
tryptophan were salt effects pronounced, while with 
uncharged analogues they were small, except at high 
salt concentrations. 
Binding data were treated according the equation 
developed by Scatchard [ 181 correlating E, the mean 
number of moles of compound bound per mole of 
protein; A, the molar concentration of unbound 
compound; N, the theoretical number of binding 
sites and k, the association constant. 
3. Results and discussion 
Although insufficient data were obtained to 
characterize fully the binding curves for each com- 
pound, some conclusions can be drawn about their 
relative ability to be bound to HSA. 
For Phe the percentage bound at various Phe con- 
centrations was determined at pH 7.35 and 9 (fig. 1). 
A considerable increase of binding was observed at 
pH 9. A similar behaviour has been reported for Trp 
[ 191. In studies of competitive binding Phe was 
found to inhibit Trp binding to HSA to a slight extent 
at pH 9, having a much smaller association constant 
than does Trp. This is in good agreement with our 
present results. The Scatchard plot of data obtained 
at pH 9 indicates that there are about 22 binding 
sites on HSA for Phe, with equal, but rather low 
affinities. (fig. 1 b). 
Binding studies with PheOMe and with dipeptide 
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Fig. 1: a) Comparison of per cent Phe bound to HSA at various free amino acid concentrations at pH 7.35 and pH 9; data 
obtained by equilibrium dialysis, 4’C; b) Scatchard plot for the binding of Phe to HSA (1% solution) at pH 9,4’C. Insert: 
binding parameters for Trp [ 191 and Phe at pH 9. 
ii/A.lB3 
Fig. 2. Binding of PheOMe (-o-_), Pro-PheOMe (-X -), Lys-TrpOMe (-A-), and Ser-TrpOMe c-o-) to HSA (1% solution). 
Scatchard plots for data obtained by equilibrium dialysis, at pH 6,4’C. 
esters were carried out at pH 6, the pH of incubation 
used in preparing protein-cytotoxic drug complexes 
[6]. HSA seems to bind PheOMe also at several, but 
equally weak sites (fig. 1). Phenylalanine peptides 
shows very little affinity for HSA, as illustrated by 
162 
Pro-PheOMe (fig. 2). No binding could be measured 
with Glu(OMe)PheOMe, Glu(PheOMe)OH, and 
DL-C@-Phe-Ser. 
The plots of ii/A vs E obtained for Tyr peptides 
indicate that the number of binding sites is not as high 
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Fig. 3. Binding of Ser-TyrOMe (-o-_), Lys-TyrOMe (-X -), 
and Glu-TyrOMe (-a-) to HSA (1% solution). Scatchard 
plots for data obtained by equilibrium dialysis at pH 6,4OC. 
as for Phe derivatives and the association constants 
also have rather low values (fig. 3). The strongest 
binding properties were observed with Trp peptides 
(fig. 2). These results are in agreement with findings 
reported in the literature [20,21] that the indole 
compounds investigated so far, including glycine 
peptides of Trp, all bind to HSA at one specific site, 
and in some cases at a few more very weak sites. 
On the basis of binding parameters found for Phe 
an explanation can be offered for the results of 
previous animal tests, which indicated, that no 
improvement of antitumour activity could be achieved 
by complexing Melphalan or its ethyl ester with 
protein carriers [6,22]. It is likely, that albumin can 
also bind a considerable amount of Melphalan in 
appropriate conditions, but the low value which is 
likely for the association constant would not favour 
transport in vivo. Our experimental result suggest, that 
the use of Melphalan peptides containing Trp would 
be more suitable for the formation of protein com- 
plexes with higher stability. Synthestic work has been 
started to prove our hypothesis by preparing the 
proposed peptide-protein complexes and to study 
their antitumour activity. 
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